Ocular Therapeutix, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Ocular Therapeutix, Inc. filed its 2026 proxy statement detailing executive compensation, director elections, and a proposal to increase the 2021 Stock Incentive Plan by 10 million shares.
NASDAQ
Ocular Therapeutix has scheduled its annual stockholders meeting for June 11, 2025, and is seeking votes on director elections, executive compensation, stock incentive plan amendments, and other corporate matters.
NASDAQ
Ocular Therapeutix is seeking stockholder approval for several key proposals at its 2025 Annual Meeting, including amendments to its stock incentive plan, employee stock purchase plan, and certificate of incorporation to provide officer exculpation.
NASDAQ
DEFA14A: Ocular Therapeutix Seeks Stockholder Approval for Increased Share Issuance and Director Elections
Ocular Therapeutix is holding its annual meeting on June 12, 2024, seeking stockholder approval for director elections, executive compensation, an increase in stock incentive plan shares, an increase in authorized common stock, and ratification of its accounting firm.
NASDAQ
Ocular Therapeutix is holding its 2024 Annual Meeting of Stockholders virtually on June 12, 2024, to vote on several proposals, including the election of directors, executive compensation, and amendments to the stock incentive plan and corporate charter.